Cite
HARVARD Citation
Cooke, K. et al. (n.d.). 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. Journal for immunotherapy of cancer. pp. A376-A377. [Online].